Phase II/III study of Gemcitabine and S-1 (GS therapy) as Neoadjuvant chemotherapy for resectable pancreatic cancer (Prep-02/JSAP-05)
Phase 2
- Conditions
- Resectable pancreatic cancer
- Registration Number
- JPRN-UMIN000009634
- Lead Sponsor
- Study group of preoperative therapy for pancreatic cancer (PREP)/Japanese Study Group of Adjuvant Therapy for pancreatic Cancer (JSAP)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 364
Inclusion Criteria
Not provided
Exclusion Criteria
1) pulmonary fibrosis or interstitial pneumonitis 2) Uncontrolled watery diarrhea 3) Active double cancer 4) Active infection 5) HBs antigen positive 6) Pregnant females, possibly pregnant females
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method